✦ LIBER ✦

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy

✍ Scribed by Stephanie L. Hines; Jeff A. Sloan; Pamela J. Atherton; Edith A. Perez; Shaker R. Dakhil; David B. Johnson; Pavan S. Reddy; Robert J. Dalton; Bassam I. Mattar; Charles L. Loprinzi

Book ID: 113507164
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 206 KB
Volume: 19
Category: Article
ISSN: 0960-9776
DOI: 10.1016/j.breast.2009.12.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effective inhibition of aromatase inhibi

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO-FAST study results

✍ Nigel J. Bundred; Ian D. Campbell; Neville Davidson; Richard H. DeBoer; Holger E 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

## Abstract ## BACKGROUND. Letrozole is safe and effective in postmenopausal women with estrogen receptor‐positive early breast cancer, but long‐term aromatase inhibitor use may cause bone loss and increase fracture risk. This study evaluated an immediate or delayed strategy of bone protection the

Incidence and management of side effects

Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women

✍ Mouridsen, Henning T. 📂 Article 📅 2006 🏛 Informa plc 🌐 English ⚖ 485 KB

Re: The Use of Zoledronic Acid in Men Re

Re: The Use of Zoledronic Acid in Men Receiving Androgen Deprivation Therapy for Prostate Cancer With Severe Osteopenia or Osteoporosis

✍ Griebling, Tomas L. 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 54 KB

P105 Zoledronic acid in the prevention o

P105 Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer

✍ N. Davidson; P. Neven; A. Llombart; N. Bundred; A. Monnier; R. DeBoer; G. Giardi 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Zoledronic acid (ZA) as adjuvant therapy

Zoledronic acid (ZA) as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells (DTC) in bone marrow (BM)

✍ A. Lin; J. Park; M. Melisko; A. Goga; M. Moasser; D. Moore; H. Rugo 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Aromatase inhibitor therapy: toxicities

Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer

✍ Susan F. Dent; Rania Gaspo; Michelle Kissner; Kathleen I. Pritchard 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 537 KB